Formulations of guanylate cyclase C agonists and methods of use
US10034836B2 · kind B2 · utility
0Cited by
38References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 2014 |
| Grant date | Jul 31, 2018 |
| Priority date | — |
| Expiry date | Jun 11, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.